Intellia Therapeutics, Inc.

Intellia Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments using CRISPR gene editing and other core technologies. The company aims to develop and commercialize potentially curative treatments for people with severe diseases. Intellia applies its proprietary technologies, including CRISPR-based gene editing technologies, oligonucleotides, and lipid nanoparticles (LNPs), to develop product candidates. Its lead product candidates are lonvoguran ziclumeran (lonvo-z or NTLA-2002) for hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z or NTLA-2001) for transthyretin (ATTR) amyloidosis. These are the first in vivo genome editing product candidates to enter Phase 3 development. These candidates are designed to treat diseases with a single intravenous (IV) infusion administered in an outpatient setting. Lonvo-z and nex-z are currently in Phase 3 clinical development. The company is preparing for the planned commercial launch of lonvo-z in the first half of 2027. Intellia and its collaboration partners are also advancing additional clinical and preclinical product candidates. The company leverages collaborations, including one with Regeneron Pharmaceuticals, Inc. (Regeneron), to expand and accelerate product candidate development.